AbbVie is also advancing its collaborations with other companies. With REGENXBIO, AbbVie is developing a gene therapy for two major eye diseases, with pivotal trial results expected in 2026.

AbbVie's growth prospects remain strong despite the impending decline in revenue from Humira. Click here to read more on why I rate ABBV stock as a Buy.

More Challenges Await AbbVie Following A Disappointing Quarter. Jul. 14, 2023 4:54 PM ET AbbVie Inc. ... So, except for Q1 2023, the company's R&D spending averaged $1.65 billion, ...

AbbVie ends a six-day losing streak with a 0.88% gain, though concerns over increased R&D costs and earnings revisions continue to weigh on investor sentiment.

AbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases of ageing with another $500 million apiece. The collaboration ...

AbbVie, known for its strong presence in immunology and oncology, has demonstrated resilience in the face of Humira’s patent expiration. The company reported robust financial results in the fourth ...

AbbVie on Thursday lowered its forecast for 2024 adjusted profit, citing the impact of $82 million in milestones, and research and development expenses related to acquisitions. The drugmaker ...

The Case for Big Bets is AbbVie’s way of underscoring its investments in the science and technology behind three of its main pillars: oncology, immunology and neuroscience. As part of this pivot in ...

AbbVie Ventures knows that challenge intimately, and leverages AbbVie’s in-house expertise as well as its network of third parties to help biotechs work through any hurdles they face.